A novel long intergenic non-coding RNA, Nostrill, regulates iNOS gene transcription and neurotoxicity in microglia.


Journal

Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974

Informations de publication

Date de publication:
06 Jan 2021
Historique:
received: 13 10 2020
accepted: 09 12 2020
entrez: 7 1 2021
pubmed: 8 1 2021
medline: 8 10 2021
Statut: epublish

Résumé

Microglia are resident immunocompetent and phagocytic cells in the CNS. Pro-inflammatory microglia, stimulated by microbial signals such as bacterial lipopolysaccharide (LPS), viral RNAs, or inflammatory cytokines, are neurotoxic and associated with pathogenesis of several neurodegenerative diseases. Long non-coding RNAs (lncRNA) are emerging as important tissue-specific regulatory molecules directing cell differentiation and functional states and may help direct proinflammatory responses of microglia. Characterization of lncRNAs upregulated in proinflammatory microglia, such as NR_126553 or 2500002B13Rik, now termed Nostrill (iNOS Transcriptional Regulatory Intergenic LncRNA Locus) increases our understanding of molecular mechanisms in CNS innate immunity. Microglial gene expression array analyses and qRT-PCR were used to identify a novel long intergenic non-coding RNA, Nostrill, upregulated in LPS-stimulated microglial cell lines, LPS-stimulated primary microglia, and LPS-injected mouse cortical tissue. Silencing and overexpression studies, RNA immunoprecipitation, chromatin immunoprecipitation, chromatin isolation by RNA purification assays, and qRT-PCR were used to study the function of this long non-coding RNA in microglia. In vitro assays were used to examine the effects of silencing the novel long non-coding RNA in LPS-stimulated microglia on neurotoxicity. We report here characterization of intergenic lncRNA, NR_126553, or 2500002B13Rik now termed Nostrill (iNOS Transcriptional Regulatory Intergenic LncRNA Locus). Nostrill is induced by LPS stimulation in BV2 cells, primary murine microglia, and in cortical tissue of LPS-injected mice. Induction of Nostrill is NF-κB dependent and silencing of Nostrill decreased inducible nitric oxide synthase (iNOS) expression and nitric oxide (NO) production in BV2 and primary microglial cells. Overexpression of Nostrill increased iNOS expression and NO production. RNA immunoprecipitation assays demonstrated that Nostrill is physically associated with NF-κB subunit p65 following LPS stimulation. Silencing of Nostrill significantly reduced NF-κB p65 and RNA polymerase II recruitment to the iNOS promoter and decreased H3K4me3 activating histone modifications at iNOS gene loci. In vitro studies demonstrated that silencing of Nostrill in microglia reduced LPS-stimulated microglial neurotoxicity. Our data indicate a new regulatory role of the NF-κB-induced Nostrill and suggest that Nostrill acts as a co-activator of transcription of iNOS resulting in the production of nitric oxide by microglia through modulation of epigenetic chromatin remodeling. Nostrill may be a target for reducing the neurotoxicity associated with iNOS-mediated inflammatory processes in microglia during neurodegeneration.

Sections du résumé

BACKGROUND BACKGROUND
Microglia are resident immunocompetent and phagocytic cells in the CNS. Pro-inflammatory microglia, stimulated by microbial signals such as bacterial lipopolysaccharide (LPS), viral RNAs, or inflammatory cytokines, are neurotoxic and associated with pathogenesis of several neurodegenerative diseases. Long non-coding RNAs (lncRNA) are emerging as important tissue-specific regulatory molecules directing cell differentiation and functional states and may help direct proinflammatory responses of microglia. Characterization of lncRNAs upregulated in proinflammatory microglia, such as NR_126553 or 2500002B13Rik, now termed Nostrill (iNOS Transcriptional Regulatory Intergenic LncRNA Locus) increases our understanding of molecular mechanisms in CNS innate immunity.
METHODS METHODS
Microglial gene expression array analyses and qRT-PCR were used to identify a novel long intergenic non-coding RNA, Nostrill, upregulated in LPS-stimulated microglial cell lines, LPS-stimulated primary microglia, and LPS-injected mouse cortical tissue. Silencing and overexpression studies, RNA immunoprecipitation, chromatin immunoprecipitation, chromatin isolation by RNA purification assays, and qRT-PCR were used to study the function of this long non-coding RNA in microglia. In vitro assays were used to examine the effects of silencing the novel long non-coding RNA in LPS-stimulated microglia on neurotoxicity.
RESULTS RESULTS
We report here characterization of intergenic lncRNA, NR_126553, or 2500002B13Rik now termed Nostrill (iNOS Transcriptional Regulatory Intergenic LncRNA Locus). Nostrill is induced by LPS stimulation in BV2 cells, primary murine microglia, and in cortical tissue of LPS-injected mice. Induction of Nostrill is NF-κB dependent and silencing of Nostrill decreased inducible nitric oxide synthase (iNOS) expression and nitric oxide (NO) production in BV2 and primary microglial cells. Overexpression of Nostrill increased iNOS expression and NO production. RNA immunoprecipitation assays demonstrated that Nostrill is physically associated with NF-κB subunit p65 following LPS stimulation. Silencing of Nostrill significantly reduced NF-κB p65 and RNA polymerase II recruitment to the iNOS promoter and decreased H3K4me3 activating histone modifications at iNOS gene loci. In vitro studies demonstrated that silencing of Nostrill in microglia reduced LPS-stimulated microglial neurotoxicity.
CONCLUSIONS CONCLUSIONS
Our data indicate a new regulatory role of the NF-κB-induced Nostrill and suggest that Nostrill acts as a co-activator of transcription of iNOS resulting in the production of nitric oxide by microglia through modulation of epigenetic chromatin remodeling. Nostrill may be a target for reducing the neurotoxicity associated with iNOS-mediated inflammatory processes in microglia during neurodegeneration.

Identifiants

pubmed: 33407594
doi: 10.1186/s12974-020-02051-5
pii: 10.1186/s12974-020-02051-5
pmc: PMC7789650
doi:

Substances chimiques

Lipopolysaccharides 0
RNA, Long Noncoding 0
Nitric Oxide Synthase Type II EC 1.14.13.39
Nos2 protein, mouse EC 1.14.13.39

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

16

Subventions

Organisme : NIGMS NIH HHS
ID : P20 GM103427
Pays : United States

Références

Open Biol. 2017 Jul;7(7):
pubmed: 28747406
Adv Exp Med Biol. 2017;1008:47-74
pubmed: 28815536
J Neuroinflammation. 2019 Apr 8;16(1):75
pubmed: 30961627
Nat Neurosci. 2013 Dec;16(12):1896-905
pubmed: 24162652
Physiol Rev. 2011 Apr;91(2):461-553
pubmed: 21527731
Stem Cell Reports. 2020 Mar 10;14(3):493-505
pubmed: 32160522
Am J Physiol Cell Physiol. 2018 Jul 1;315(1):C52-C61
pubmed: 29631367
J Clin Invest. 2017 Sep 1;127(9):3201-3209
pubmed: 28714861
J Neuropathol Exp Neurol. 2019 Mar 1;78(3):268-282
pubmed: 30715406
Methods Mol Biol. 2018;1784:77-86
pubmed: 29761389
J Neuroinflammation. 2015 Jun 06;12:114
pubmed: 26048578
Nat Rev Genet. 2014 Jan;15(1):7-21
pubmed: 24296535
Oncol Rep. 2017 Jan;37(1):3-9
pubmed: 27841002
Mol Neurobiol. 2016 Dec;53(10):6709-6715
pubmed: 26659872
Nitric Oxide. 2010 Sep 15;23(2):75-93
pubmed: 20438856
Nat Neurosci. 2007 Nov;10(11):1387-94
pubmed: 17965659
Mediators Inflamm. 2019 Dec 3;2019:8626703
pubmed: 31885500
Mov Disord. 2020 Jan;35(1):20-33
pubmed: 31680318
Nat Rev Immunol. 2015 Sep 15;15(9):545-58
pubmed: 26250739
Cell. 2010 Mar 19;140(6):918-34
pubmed: 20303880
Nat Rev Genet. 2016 Jan;17(1):47-62
pubmed: 26666209
Immunity. 2019 Jan 15;50(1):253-271.e6
pubmed: 30471926
Annu Rev Physiol. 2017 Feb 10;79:619-643
pubmed: 27959620
J Neurosci. 2013 Mar 6;33(10):4216-33
pubmed: 23467340
Adv Exp Med Biol. 2017;1008:223-252
pubmed: 28815542
Annu Rev Immunol. 2009;27:119-45
pubmed: 19302036
Free Radic Res. 2018 May;52(5):507-543
pubmed: 29589770
Nat Rev Genet. 2020 Feb;21(2):102-117
pubmed: 31729473
J Neuroinflammation. 2018 Apr 10;15(1):103
pubmed: 29636074
Sci Adv. 2017 Sep 27;3(9):eaao2110
pubmed: 28959731
Cell Death Dis. 2018 Jul 23;9(8):803
pubmed: 30038357
Neurochem Int. 2019 Nov;130:104331
pubmed: 30423423
Front Cell Neurosci. 2020 Aug 06;14:198
pubmed: 32848611
Mol Ther Nucleic Acids. 2018 Dec 7;13:450-463
pubmed: 30388619
J Neuroinflammation. 2014 Jun 03;11:98
pubmed: 24889886
J Neuroimmune Pharmacol. 2020 Sep;15(3):390-399
pubmed: 31325121
Cell Tissue Res. 2018 Jan;371(1):55-71
pubmed: 29079882
Brain Res. 2015 Dec 2;1628(Pt B):288-297
pubmed: 26341532
Adv Pharmacol. 2018;82:57-83
pubmed: 29413528
J Transl Autoimmun. 2020 Mar 17;3:100044
pubmed: 32743525
Science. 2013 Aug 16;341(6147):789-92
pubmed: 23907535
Cell Cycle. 2015;14(2):253-60
pubmed: 25607649
Front Pharmacol. 2019 Mar 22;10:286
pubmed: 30967783
Pharmacol Ther. 2013 Sep;139(3):313-26
pubmed: 23644076
Annu Rev Biochem. 2012;81:145-66
pubmed: 22663078
Cold Spring Harb Perspect Biol. 2015 Sep 09;8(1):a020560
pubmed: 26354893
Stroke. 2019 Jul;50(7):1850-1858
pubmed: 31167620
Am J Physiol Cell Physiol. 2017 Mar 1;312(3):C254-C262
pubmed: 27974299
Trends Mol Med. 2019 Feb;25(2):112-123
pubmed: 30578090
Brain Circ. 2016 Jul-Sep;2(3):126-128
pubmed: 30276287
Front Microbiol. 2018 Dec 04;9:2966
pubmed: 30564215
Trends Immunol. 2014 Sep;35(9):408-19
pubmed: 25113636
Nature. 2019 Sep;573(7772):75-82
pubmed: 31316211
Biochem Pharmacol. 2018 Sep;155:110-123
pubmed: 29944870
Cell. 2013 Mar 14;152(6):1298-307
pubmed: 23498938
FASEB J. 2015 Sep;29(9):3595-611
pubmed: 26065857
Biomolecules. 2020 Jul 14;10(7):
pubmed: 32674342
Cell Rep. 2018 Nov 6;25(6):1511-1524.e6
pubmed: 30404006
Sci Rep. 2018 May 29;8(1):8346
pubmed: 29844328
Biochim Biophys Acta Rev Cancer. 2020 Jan;1873(1):188316
pubmed: 31639408
Genome Biol. 2017 Oct 31;18(1):206
pubmed: 29084573
Nat Rev Mol Cell Biol. 2018 Mar;19(3):143-157
pubmed: 29138516
Nat Rev Immunol. 2011 Oct 25;11(11):775-87
pubmed: 22025055
J Neurosci Methods. 2005 Dec 15;149(2):110-20
pubmed: 16084598
Cell Death Differ. 2019 Jan;26(1):130-145
pubmed: 29666475
FASEB J. 2017 Mar;31(3):1215-1225
pubmed: 27979905
Science. 2005 May 27;308(5726):1314-8
pubmed: 15831717
Front Mol Neurosci. 2019 Oct 17;12:254
pubmed: 31680858
Nucleic Acids Res. 2019 Nov 4;47(19):9967-9989
pubmed: 31501881
J Biol Chem. 2017 Jul 28;292(30):12375-12382
pubmed: 28615453
Nature. 2011 Aug 28;477(7364):295-300
pubmed: 21874018
Front Mol Neurosci. 2019 Sep 10;12:215
pubmed: 31551710
Noncoding RNA. 2019 Apr 19;5(2):
pubmed: 31010202
J Microsc. 2014 Jul;255(1):7-19
pubmed: 24831993
J Immunol. 2016 Mar 15;196(6):2799-2808
pubmed: 26880762

Auteurs

Nicholas W Mathy (NW)

School of Medicine, Creighton University, 2500 California Plaza, Omaha, NE, 68178-0010, USA.

Olivia Burleigh (O)

Biology Department, Creighton University, 2500 California Plaza, Omaha, NE, 68178-0100, USA.

Andrew Kochvar (A)

Biology Department, Creighton University, 2500 California Plaza, Omaha, NE, 68178-0100, USA.

Erin R Whiteford (ER)

School of Medicine, Creighton University, 2500 California Plaza, Omaha, NE, 68178-0010, USA.

Matthew Behrens (M)

University of Nebraska College of Medicine, 987020 Nebraska Medical Center, Omaha, NE, 68198-7020, USA.

Patrick Marta (P)

School of Medicine, Creighton University, 2500 California Plaza, Omaha, NE, 68178-0010, USA.

Cong Tian (C)

School of Medicine, Creighton University, 2500 California Plaza, Omaha, NE, 68178-0010, USA.

Ai-Yu Gong (AY)

School of Medicine, Creighton University, 2500 California Plaza, Omaha, NE, 68178-0010, USA.

Kristen M Drescher (KM)

School of Medicine, Creighton University, 2500 California Plaza, Omaha, NE, 68178-0010, USA.

Peter S Steyger (PS)

School of Medicine, Creighton University, 2500 California Plaza, Omaha, NE, 68178-0010, USA.

Xian-Ming Chen (XM)

School of Medicine, Creighton University, 2500 California Plaza, Omaha, NE, 68178-0010, USA.

Annemarie Shibata (A)

Biology Department, Creighton University, 2500 California Plaza, Omaha, NE, 68178-0100, USA. ash33271@creighton.edu.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH